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Negative correlation of single-cell PAX3:FOXO1 expression
with tumorigenicity in rhabdomyosarcoma
Carla Regina1, Ebrahem Hamed1 , Geoffroy Andrieux2,3,4, Sina Angenendt1 , Michaela Schneider1, Manching Ku1 ,
Marie Follo5 , MarcoWachtel6, Eugene Ke7, Ken Kikuchi8 , Anton G Henssen9, Beat W Schäfer6, Melanie Boerries2,3,4,13 ,
Amy J Wagers10,11,12 , Charles Keller14 , Simone Hettmer1,13,15
Rhabdomyosarcomas (RMS) are phenotypically and functionally
heterogeneous. Both primary human RMS cultures and low-
passage Myf6Cre,Pax3:Foxo1,p53 mouse RMS cell lines, which
express the fusion oncoprotein Pax3:Foxo1 and lack the tumor
suppressor Tp53 (Myf6Cre,Pax3:Foxo1,p53), exhibit marked het-
erogeneity in PAX3:FOXO1 (P3F) expression at the single cell level.
In mouse RMS cells, P3F expression is directed by the Pax3
promoter and coupled to eYFP. YFPlow/P3Flow mouse RMS cells
included 87% G0/G1 cells and reorganized their actin cytoskeleton
to produce a cellular phenotype characterized by more efficient
adhesion and migration. This translated into higher tumor-
propagating cell frequencies of YFPlow/P3Flow compared with
YFPhigh/P3Fhigh cells. Both YFPlow/P3Flow and YFPhigh/P3Fhigh cells
gave rise to mixed clones in vitro, consistent with fluctuations
in P3F expression over time. Exposure to the anti-tropomyosin
compound TR100 disrupted the cytoskeleton and reversed en-
hanced migration and adhesion of YFPlow/P3Flow RMS cells. Het-
erogeneous expression of PAX3:FOXO1 at the single cell level may
provide a critical advantage during tumor progression.
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Introduction
Rhabdomyosarcoma, the most common soft tissue sarcoma in chil-
dren and adolescents, comprises two main genotypes defined by the
presence or absence of PAX gene rearrangements (1, 2). Canonical PAX
translocations juxtapose the N-terminus of the paired-box genes PAX3
or PAX7 with the C terminus of the transcription factor FOXO1 (3). PAX3:
FOXO1 (P3F) has been detected in 55% and PAX7:FOXO1 (P7F) in 22%
of alveolar histology RMS tumors (4). Both PAX gene fusions act as
major oncogenic drivers. P3F was shown to cooperate with the
master transcription factors MYOG, MYOD, and MYCN to recruit
superenhancers and establish autoregulatory loops that enforce
its myogenic and oncogenic transcriptional program (5). P3F knock-
down in human and mouse RMS cell lines was linked to a decrease in
proliferation rates (6, 7). Patients with RMS harboring P3F are more
likely to present with metastatic disease and relapse quickly de-
spite aggressive therapy. Extremely poor survival rates call for a
deeper understanding of the biology of P3F+ RMS (2).
Several independent studies confirm that ectopic P3F alone does
not induce RMS tumors in mice (14, 8). Additional oncogenetic hits
are necessary to initiate P3F-expressing myogenic tumors from
cells of both myogenic and non-myogenic lineage (9, 15), provided
that ectopic P3F is expressed before the introduction of these
additional oncogenic events (16). This observation is consistent
with genomic subclonality analyses in human tumors identifying
P3F as a founding event in P3F+ RMS (11). PAX-translocated RMS
tumors have extremely low overall mutation rates (10), but they
tend to harbor regions of genomic amplification, often involving the
proto-oncogene MYCN, the cell cycle regulator CDK4, and the TP53
pathway modulator MDM2 (11, 12). Indeed, transcriptional profiling
indicated widespread inactivation of TP53 signaling in P3F+ RMS
(13). Keller et al established a mouse model of P3F-expressing
alveolar RMS by combining conditional activation of biallelic P3F
expression from the endogenous Pax3 locus and homozygous
deletion of Tp53 inMyf6-expressing maturing mouse myofibers (14).
In this system, P3F is linked to an eYFP fluorescent marker gene,
which is expressed as a second cistron downstream from an in-
ternal ribosome entry site (IRES) on the samemRNA, so that P3F and
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YFP expression strongly correlate and YFP fluorescence can be used
as a surrogate for P3F transcription from the Pax3 locus (17, 15). YFP
activity in such Myf6Cre+/−,Pax3:Foxo1+/+,p53−/− mouse RMS tu-
mors was previously shown to differ between individual tumor cells
and fluctuate over time, consistent with heterogeneous and dy-
namic expression of P3F at the single cell level (18). This study
aimed to clarify the functional impact of variable P3F expression at
the cellular level in Myf6Cre+/−,Pax3:Foxo1+/+,p53−/− mouse RMS
tumors. Our observations reveal higher tumor-propagating po-
tential of P3Flow cell states than P3Fhigh cell states.
Results
Variable cellular P3F dose in mouse and human RMS cells
In mouse U23674 and U21459 cells (established from Myf6Cre+/−,
Pax3:Foxo1+/+,p53−/− mouse sarcomas), expression of P3F is di-
rected by the Pax3 promoter and coupled to an eYFP fluorescent
marker, which is activated as a second cistron downstream from an
encephalomyocarditis virus–derived IRES (17). As previously de-
scribed (18), the U23674 and U21459 cell pools are composed of cells
expressing different YFP levels. To explore whether similar cell-to-
cell variability of P3F transcript levels may also occur in human RMS,
single-cell digital droplet PCR was performed to quantify the ab-
solute number of P3F and GAPDHmRNAmolecules per single cell in
three human RMS patient–derived primary cell cultures (IC-pPDX-
35, RMSZH003, and SJRHB013759_X1) and in two human cell lines
(Rh41 and Rh30) (Figs 1A and B and S1B and Table S1). P3F was
detected in 41 of 83 (49%) GAPDH-expressing IC-pPDX-35 cells, 17 of
79 (22%) GAPDH-expressing RMSZH003 cells, 21 of 87 (24%) GAPDH-
expressing SJRHB013759_X1 cells, 53 of 85 (62%) GAPDH-expressing
Rh41 cells, and 12 of 46 (26%) GAPDH-expressing Rh30 cells (Fig 1A).
Normalization of P3F expression based on GAPDH expression
highlighted that cells with equivalent numbers of GAPDH mRNA
molecules displayed substantial variation in P3F expression (Fig 1B
and C). We conclude that, similar to what was observed in Myf6-
Cre,Pax3:Foxo1,p53mouse RMS tumors (18), there is substantial cell-
to-cell variability in P3F expression in the human RMS cell pool.
Fluctuation of P3F expression in mouse RMS cells between P3Fhigh
and P3Flow states
To further investigate the behavior of RMS cells expressing different
P3F levels, U23674 cells were subfractionated by fluorescence-
activated cell sorting (FACS) to discriminate YFPhigh (Y-H) and
YFPlow (Y-L) cell subsets (Fig S1A; purity of sorted populations >98%),
with gates determined based on fluorescence detection in YFP-
negative and YFP-positive control samples. On average, U23674
cells contained 26% ± 8.5% YFPhigh and 74% ± 8.5% YFPlow cells. RT-
qPCR (Fig 2A) and Western blot (Fig 2B) confirmed that the YFPhigh
(Y-H) subset of U23674 cells expressed higher levels of P3F than
significantly lower P3F levels in YFPlow (Y-L) and unfractionated (U)
U23674 cells, and absent P3F in normal skeletal muscle (SM, Fig 2A).
For each U23674 cell subset (i.e., unfractionated, YFPhigh/P3Fhigh
or YFPlow/P3Flow cells), 20 cells per well were plated into 96-well
plates (Fig 2C). Clones formed in 291 of 1,220 (23.9%) YFPlow/P3Flow
U23674 cells, 64 of 1,220 (5.2%) YFPhigh/P3Fhigh U23674 cells, and 114
of 1,220 (9.3%) unfractionated U23674 cells (Fig 2D; P < 0.001). These
differences were confirmed in three independent experiments.
Thus, surprisingly, YFPlow/P3Flow U23674 cells exhibited higher
clonal activity in vitro than YFPhigh/P3Fhigh U23674 cells.
Clones originating from unfractionated, YFPhigh/P3Fhigh and
YFPlow/P3Flow U23674 cells were allowed expansion for up to 11 d
(Fig 2C). Average expression of P3F mRNA in day 11 (d11) clones
originating from unfractionated, YFPhigh/P3Fhigh and YFPlow/P3Flow
U23674 cells was determined by RT-QPCR and found to be similar
(Fig 2E). The proportion of YFPhigh/P3Fhigh and YFPlow/P3Flow cells in
d11 clones was further analyzed by FACS. Interestingly, all d11
clones, including those arising from YFPlow/P3Flow cells, contained
both YFPlow/P3Flow and YFPhigh/P3Fhigh cells. Specifically, there were
13.2% ± 7.4% YFPhigh/P3Fhigh cells in clones originating from un-
fractionated cells compared with 27.5% ± 26.2% YFPhigh/P3Fhigh cells
in clones originating from YFPhigh/P3Fhigh cells (P = 0.93) and 7.9% ±
2.6% YFPhigh/P3Fhigh cells in clones originating from YFPlow/P3Flow
cells (P = 0.54; Fig 2F). Thus, remarkably, when cultured in vitro,
YFPlow/P3Flow U23674 cells gave rise to clones containing YFPhigh/
P3Fhigh as well as YFPlow/P3Flow cells and vice versa. This obser-
vation is consistent with dynamic expression of P3F in single U23674
cells, as previously reported by Kikuchi et al (18).
For comparison, we evaluated the dynamics of expression in
myogenic cells of a fluorescent protein that was not linked to P3F
expression. C2C12 mouse myoblasts were transduced with empty
vector (EV) pMSCV-Flag-IRES-GFP retroviruses, and EV-GFPhigh and
EV-GFPlow cells were separated by FACS sorting (purity > 98%) (Fig
S2A). Twenty sorted EV-GFPhigh and EV-GFPlow cells per well were
plated into 96-well plates. Clones were allowed to expand for 10 d
and analyzed by FACS. In contrast to results obtained when YFP was
coupled to P3F expression (Fig 2), EV-GFP–expressing cells showed
stable fluorescence phenotypes and similar clonal efficiencies. In
particular, clonal efficiency was 6.3% for EV-GFPhigh and 6.4% for EV-
GFPlow cells (Fig S2B). Day 10 (d10) clones arising from EV-GFPhigh
cells contained 99% ± 1.3% GFPhigh cells, whereas d10 clones
originating from EV-GFPlow cells contained 0% ± 0% GFPhigh cells (Fig
S2C and D). These data provide further support to the notion that
dynamic expression patterns seen in cells expressing YFP coupled
to P3F reflect variation in P3F expression.
Changes in P3F dose in mouse RMS cells in response to
environmental changes
To examine if changes in the cell environment influenced the
proportion of YFPhigh/P3Fhigh and YFPlow/P3Flow U23674 cells, we
measured the percentage of YFPhigh/P3Fhigh cells in U23674 and
U21459 cells grown in medium containing different glutamine and
glucose concentrations (Figs S3A and B and S4A and B), plated at
different densities (Figs S3C, D, and F–H and S4C), cultured on
surfaces covered with different matrices (Figs S3E and S4F) and
exposed to different drugs (Figs S3I–K and S4D and E). We observed
that higher glutamine levels led to an increase in the percentage of
YFPhigh/P3Fhigh U23674 cells (2% ± 0.3% versus 15% ± 0.8% YFPhigh/
P3Fhigh cells in medium containing 0.05 mM versus 4 mM glutamine,
P = 0.001, Fig S3A) and U21459 cells (2.3% ± 0.1% versus 4.4% ± 0.2%
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Figure 1. Cell-to-cell variability in P3F expression in RMS.
(A, B) Evaluation of P3F and GAPDH mRNA expression at the single-cell level by RT-digital droplet PCR in IC-pPDX-35 (n = 88 cells), RMSZH003 (n = 88 cells), and
SJRHB013759_X1 (n = 88 cells) human patient-derived RMS cell cultures as well as Rh41 (n = 88 cells) and Rh30 (n = 48 cells) human RMS cell lines. (A) P3F expression was
detected in 22–49% of GAPDH-expressing cells in patient-derived RMS cell cultures and in 26–62% of GAPDH-expressing cells in human RMS cell lines. (B) Remarkable cell-
to-cell heterogeneity in P3F expression as evidenced by representation of P3F/GAPDH ratios. Each dot represents themRNA content of one cell. Bars indicate medians ±
interquartile ranges. (C) 2D representation of droplets generated from two IC-pPDX-35 cells with P3Fhigh (upper panel, marked in green) or P3Flow (bottom panel, marked in
red) profiles with the same level of GAPDH mRNA. Please see Fig S1B for single-cell P3F and GAPDH expression in each line.
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YFPhigh/P3Fhigh cells in medium containing 0.05 mM versus 4 mM
glutamine, P < 0.0001, Fig S4A). Changes in glucose concentrations in
the medium did not affect the percentage of YFPhigh/P3Fhigh U23674
and U21459 cells (Fig S3B).
Differences in the extracellular matrix used for cell culture also
influenced the percentage of YFPhigh/P3Fhigh cells. When cells were
grown on laminin or Matrigel, the percentage of YFPhigh/P3Fhigh
U23674 cells was reduced compared with cells grown on uncoated
surfaces (21% ± 0.4% YFPhigh/P3Fhigh cells on laminin and 13% ± 0.6%
YFPhigh/P3Fhigh cells on Matrigel versus 32% ± 1.2% YFPhigh/P3Fhigh
cells on uncoated surfaces; P < 0.001, Fig S3E). Exposure to fibro-
nectin did not alter the percentage of YFPhigh/P3Fhigh U23674 cells
(Fig S3E). Exposure to Matrigel, but not laminin or fibronectin, also
reduced the percentage of YFPhigh/P3Fhigh U21459 cells compared
with culture uncoated surfaces (2.1% ± 0.4% YFPhigh/P3Fhigh cells on
Matrigel versus 3.9% ± 0.6% YFPhigh/P3Fhigh cells on uncoated
surfaces; P < 0.05, Fig S4F). Moreover, culture at higher cell densities,
achieved by seeding cells in triangle-shaped wells (Fig S3C) or at
higher cell numbers per well (Fig S3D and F–H), increased the
percentage of YFPhigh/P3Fhigh U23674 and U21459 cells. For example,
cells seeded at 30,000 cells per well on uncoated surfaces con-
tained more YFPhigh/P3Fhigh cells than those seeded at 5,000 cells
per well on uncoated surfaces (44% ± 0% versus 25% ± 3.4%; P =
0.001; Fig S3D).
Finally, U23674 and U21459 cells were treated with two chemo-
therapy drugs used for treatment of RMS (vincristine, dactinomycin;
48 h exposure each) and with the anti-tropomyosin compound TR100
for 12 h. Vincristine raised the percentage of YFPhigh/P3Fhigh U23674
cells (60% ± 0.8% versus 41% ± 1.1% YFPhigh/P3Fhigh cells among
vincristine-treated compared with control cells; P = 0.0001; Fig S3I)
and U21459 cells (4.5% ± 0.4% versus 3.6% ± 0.2% YFPhigh/P3Fhigh cells
among vincristine-treated compared with control cells; P < 0.05; Fig
S4D), and dactinomycin decreased the percentage of YFPhigh/P3Fhigh
U23674 cells (33.4% ± 3% versus 43.4% ± 1.1%; YFPhigh/P3Fhigh cells
among dactinomycine-treated comparedwith control cells; P = 0.006;
Fig S3J) and U21459 cells (3.7% ± 0.4% versus 5.6% ± 0.6% YFPhigh/
P3Fhigh cells among dactinomycine-treated compared with control
cells; P < 0.05; Fig S4E). Exposure to TR100 did not change the pro-
portion of YFPhigh/P3Fhigh and YFPlow/P3Flow U23674 cells (Fig S3K).
Extended analyses revealed reduced absolute numbers of YFPlow
and YFPhigh cells exposed to vincristine and low-glutamine conditions
(50,008 ± 0 Vincristine-exposed and 48,791 ± 1,865 glutamine-deprived
versus 121,727 ± 1,821 control YFPlow cells, P < 0.01 and 25,992 ± 0
vincristine-exposed and 25,210 ± 964 glutamine-deprived versus
Figure 2. Higher clonogenic activity of YFPlow/P3Flow than YFPhigh/P3Fhigh mouse U23674 RMS cells.
Themouse RMS cell line U23674 was sorted into YFPhigh/P3Fhigh and YFPlow/P3Flow cells (purity > 98%). (A, B) RT-QPCR and (B) WB demonstrated enrichment of P3F in the
YFPhigh (Y-H) compared with the YFPlow (Y-L) and unfractionated (U) cell subsets. Skeletal muscle cells served as P3Fneg control cells. (C, D) Clonally sorted YFPlow/P3Flow
cells exhibited significantly higher clonal activity (291 [23.9%] clones out of 1,220 cells plated) than YFPhigh/P3Fhigh (64 [5.2%] clones out of 1,220 cells plated) and
unfractionated U23674 cells (114 [9.3%] clones out of 1,220 cells plated). (C, E, F) The composition of clones arising from unfractionated, YFPhigh/P3Fhigh and YFPlow/P3Flow
U23674 cells was analyzed 11 d after plating by (E) RT-QPCR (four clones per cell subset analyzed) and by (F) FACS (three clones per cell subset analyzed): (E) P3F expression
levels in clones arising from unfractionated, YFPhigh/P3Fhigh, and YFPlow/P3Flow cells were similar. (F) Clones arising from unfractionated, YFPhigh/P3Fhigh, and YFPlow/P3Flow
contained a mix of YFPhigh and YFPlow cells. Differences in clonal activity were evaluated for statistical significance by chi square test; differences in P3F expression and
cell composition by one-way ANOVAs (****P < 0.001; ***P < 0.01; **P < 0.01; ns P ≥ 0.05). All experiments were replicated three times. Please see Fig S2 for clonal expansion of
C2C12 cells transduced with retroviruses expressing GFP. Please see Fig S3 for differences in the proportion of YFPhigh U23674 cells cultured under different conditions.
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68,274 ± 1,016 control YFPhigh cells, P < 0.01); dactinomycin exposure
only resulted in a trend towards lower absolute numbers of YFPhigh
cells (43,146 ± 754 versus 68,274 ± 1,016 control YFPhigh cells, P = ns, Fig
S5A and B). The overall distribution of YFPhigh and YFPlow cells across
cell cycle phases remained the same for all conditions (Fig S5A, B, E,
and F). Generally, YFPlow/P3Flow cells included more cells in G0/G1
stages compared with YFPhigh/P3Fhigh cells (Figs 3D and E and S5A and
B). However, changes in absolute cell numbers correlated with higher
percentages of apoptotic YFPlow and YFPhigh cells exposed to vin-
cristine (9.0% ± 1.7% vincristine-exposed versus 4.3% ± 2.8% control
Figure 3. Higher tumor-propagating activity of YFPlow/P3Flow than YFPhigh/P3Fhigh mouse U23674 RMS cells.
(A) Unfractionated (U), YFPhigh/P3Fhigh (Y-H), and YFPlow/P3Flow (Y-L) U23674 cells were implanted into the extremity muscles of NOD.SCID mice and allowed to expand
for up to 4 mo. (B) YFPlow/P3Flow cells formed significantly more tumors at the injection sites than YFPhigh/P3Fhigh and unfractionated U23674 cells. (C) Limiting dilution
analysis revealed significantly higher tumor-repopulating cell frequencies within the YFPlow/P3Flow than the YFPhigh/P3Fhigh subset of cells: 1 in 7,781 YFPhigh/P3Fhigh U23674
cells (95% confidence interval: 1 in 2,332–25,964 cells) versus 1 in 65 YFPlow/P3Flow U23674 cells (95% confidence interval: range 1 in 28–151 cells; P < 0.0001). (D, E)Hoechst
33342 staining determined YFPlow/P3Flow cells contained 87% ± 0.2% cells in the G0/G1 phases, and 11% ± 0.3% cells in the G2/M phases of the cell cycle. YFPhigh/P3Fhigh
cells contained 46% ± 3.7% cells in G0/G1, and 49% ± 3.2% cells in G2/M. (F, G) The composition of tumors arising from unfractionated, YFPhigh/P3Fhigh and YFPlow/P3Flow
U23674 cells was analyzed by (F) Western blotting (two to three clones per cell subset analyzed) and by (G) FACS (two to three clones per cell subset analyzed): (F) P3F
expression levels in clones arising from unfractionated, YFPhigh/P3Fhigh, and YFPlow/P3Flow cells were similar. (G) Tumors arising from unfractionated, YFPhigh/P3Fhigh, and,
notably, YFPlow/P3Flow cells contained a mix of YFPhigh and YFPlow cells. Differences in tumor propagating capacity were evaluated for statistical significance by log-rank
(Mantel-Cox) tests; differences in cell composition by ordinary one-way ANOVAs (ns P ≥ 0.05). Limiting dilution analyses were performed as described by Bonnefoix et al
(51) using the limdil function of the StatMod package (author GK Smyth, http://bioinf.wehi.edu.au/software/limdil/). Experiments were replicated three times.
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YFPlow cells, P < 0.5 and 5.8% ± 0.7% vincristine-exposed versus 2.5% ±
1.5% control YFPhigh cells, P < 0.001, Fig S5C and D) and a lower
percentage of G2/M YFPhigh cells cultured in low-glutamine condi-
tions (17.0% ± 12.8% glutamine-deprived versus 40.6 ± 3.1 control G2/M
YFPhigh cells, P > 0.01, Fig S5F). Taken together, our observations do not
indicate that high P3F levels protect cells from stress-induced ap-
optosis by inducing a G2/M block.
Higher tumor-propagating capacity of P3Flow/YFPlow compared
with P3Fhigh/YFPhigh mouse RMS cells
As YFPlow/P3Flow U23674 cells formed significantly more clones than
YFPhigh/P3Fhigh U23674 cells, we next examined the ability of YFPlow/
P3Flow and YFPhigh/P3Fhigh U23674 cells to form tumors in immuno-
compromised mice immediately after sorting. For each U23674 cell
subset (i.e., unfractionated, YFPhigh/P3Fhigh, and YFPlow/P3Flow cells),
500 cells each were injected into the cardiotoxin preinjured gas-
trocnemius muscles of NOD.SCID recipients (Fig 3A). Secondary tumors
developed in five out of six mice injected with YFPlow/P3Flow U23674
cells, two out of six mice injected with YFPhigh/P3Fhigh U23674 cells, and
three out of sixmice injected with unfractionated U23674 cells (P < 0.05,
Fig 3B). These differences were confirmed in three independent trans-
plantation experiments. Consistent with these observations, limiting
dilution analyses (1–5,000 cells implanted in a total of four injections
each) revealed that the frequency of tumor-repopulating cells was 1
in 7,781 YFPhigh/P3Fhigh U23674 cells (95% confidence interval: 1 in
2,332 to 25,964 cells) versus 1 in 65 YFPlow/P3Flow U23674 cells (95%
confidence interval: range 1 in 28 to 151 cells; P < 0.0001) (Fig 3C and
Table S2). Thus, YFPlow/P3Flow U23674 cells clearly exhibited higher
tumor-propagating capacity than YFPhigh/P3Fhigh U23674 cells.
It was previously shown that YFP fluorescence in U23674 cells is
markedly increased during cell division (18). We therefore used
Hoechst 33342 staining to confirm that YFPhigh/P3Fhigh cells con-
tained significantly more cells in the G2/M stages of the cell cycle
compared with YFPlow/P3Flow cells (49% ± 3.2% versus 11% ± 0.3%; P <
0.0001, Fig 3D and E). In contrast, YFPlow/P3Flow cells, which
exhibited significantly higher tumor-propagating capacity, included
more cells in G0/G1 stages comparedwith YFPhigh/P3Fhigh cells (87% ±
0.2% versus 46% ± 3.7%; P < 0.0001, Fig 3D and E).
P3F/YFP expression in allograft tumor cells was evaluated by
Western blot (Fig 3F) and by FACS (Fig 3G). Again, YFPhigh/P3Fhigh cells
were detected in allograft tumors originating from unfractionated
U23674 cells (20.9% ± 12.6%), YFPhigh/P3Fhigh (22.2 ± 26.2), and YFPlow/
P3Flow U23674 cells (7.8% ± 2.6%) (Fig 3G). Differences in the per-
centage of YFPhigh/P3Fhigh cells did not reach statistical significance.
Infiltrating and surrounding host cells may account for YFPlow/P3Flow
cells in allograft tissue arising from transplanted YFPhigh/P3Fhigh cells.
However, the presence of YFPhigh/P3Fhigh cells in tumors originating
from YFPlow/P3Flow U23674 cells (Fig 3G) further supports dynamic
expression of the fusion oncogene in U23674 cells.
No effect of P3F expression levels on the proportion of apoptotic
cells in RMS
Higher P3F levels in tumor cells may be toxic and induce cell death,
thereby accounting for lower clonogenic and tumor-propagating
capacity of YFPhigh/P3Fhigh U23674 cells. Annexin V (Ann V) staining
was used to demonstrate similar rates of living (80% ± 11.5% versus
74.7% ± 8.8%, P > 0.99) and apoptotic (13.4% ± 8% versus 7.6% ± 3.5%,
P > 0.99) YFPhigh/P3Fhigh and YFPlow/P3Flow U23674 cells. There
was a trend towards lower percentages of necrotic/late apoptotic
YFPhigh/P3Fhigh versus YFPlow/P3Flow U23674 cells (5.7% ± 6.1% versus
15.3% ± 6.3%, P = 0.09), but these differences did not reach statistical
significance (Fig 4A and B). These observations indicate that dif-
ferences in the efficiency of tumor and clone formation by YFPhigh/
P3Fhigh U23674 cells are not due to higher rates of apoptosis among
cells expressing higher levels of the fusion oncogene. In U23674
cells, YFP and P3F are expressed from the targeted Pax3:Foxo1-ires-
eYFP allele (18), which allows for siGFP-induced knockdown of P3F
expression (Figs 4C and S6A). As published previously (6, 7), P3F
silencing reduced the proliferation rate of U23674 cells (Fig 4D). Yet,
similar to data obtained with YFPhigh/P3Fhigh and YFPlow/P3Flow
U23674 cells, there were no significant differences in the rates of
living (73.7% ± 9% versus 67% ± 13.5%, P = 0.36), apoptotic (8.2% ±
4.4% versus 11.8% ± 5.1%, P > 0.99), and necrotic cells (14.3% ± 5.2%
versus 17.1% ± 9.3%, P > 0.99) between U23674 cells transfected with
scrambled (Scr) control siRNA or with siGFP (Fig 4E and F). Ex-
pression of cleaved caspase 3 (Cl-Casp 3) and cleaved PARP (Cl-
Parp) also did not change after Pax3:Foxo1 silencing (Fig 4G).
P3F was also silenced in the high-passage human RMS cell lines
Rh30 (Fig S6B) and Rh5 (Fig S6E). Similar to effects in U23674 cells,
P3F silencing reduced the proliferation rate of Rh30 cells (Fig S6C)
and Rh5 cells (Fig S6F). Expression of cleaved caspase three and
cleaved PARP likewise did not change after Pax3:Foxo1 silencing in
Rh30 cells (Fig S6D) or in Rh5 cells (Fig S6G).
Differential regulation of genes involved in ECM-receptor
interaction and focal adhesion in YFPlow/P3Flow versus
YFPhigh/P3Fhigh mouse RMS cells
To further delineate the underpinnings of differences in clonal
activity and tumor-propagating capacity of U23674 cell subsets,
the gene expression profiles of YFPhigh/P3Fhigh, YFPlow/P3Flow, and
unfractionated U23674 cells were examined immediately after
sorting (Clariom S Assay, mouse; Affymetrix). This analysis revealed
profound differences in the transcriptome of YFPhigh/P3Fhigh versus
YFPlow/P3Flow and unfractionated U23674 cells (Fig 5A). We focused
our subsequent analyses on transcripts that were differentially
regulated between YFPlow/P3Flow and YFPhigh/P3Fhigh U23674 cells
(Table S3, logFC < −1 or >1, false discovery rate [FDR] < 0.01). Themost
significantly enriched pathways among these differentially regu-
lated genes included cell junction, plasma membrane region, ex-
tracellular matrix, and cell surface (FDR < 0.05, Fig 5B and Table S4).
Transcripts involved in focal adhesion (Fig S7) and regulation of the
actin cytoskeleton (Fig S8) were differentially expressed in YFPhigh/
P3Fhigh cells versus YFPlow/P3Flow cells. Differentially regulated can-
didate genes included Integrin α 8 (Itga8), Cadherin 4 (Cdh4), Rho
family GTPase 2 (Rnd2), Integrin α 5 (Itga5), Thrombospondin 3
(Thbs3), EGF containing Fibulin Extracellular Matrix Protein 1 (Efemp1),
and Laminin Subunit Alpha 5 (Lama5). QRT-PCR in siGFP compared
with control and scramble U23674 cells confirmed that lower P3F
dose (Fig 5C) was associated with lower levels of Itga8 (Fig 5D) (16,
17) and Cdh4 (Fig 5E) (18), both involved in cell–cell adhesion.
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Figure 4. Lower P3F dose did not change the proportion of apoptotic cells in mouse U23674 RMS cells stained with Annexin V (Ann V).
(A, B) The proportions of alive Ann V-/7AAD- and apoptotic Ann V+/7AAD-cells among YFPhigh/P3Fhigh (Y-H) and YFPlow/P3Flow (Y-L) U23674 cell subsets were similar.
(C) There was a trend towards lower percentages of necrotic/late apoptotic Ann V+/7AAD+ Y-H cells (C) P3F silencing in siGFP U23674 mouse RMS cells compared with
control (ctrl) cells and cells exposed to scramble (scr) siRNA. (D) Reduced P3F expression in si-GFP U23674 cells correlated with lower proliferation rates compared with
control and scramble cells. (E, F) The proportions of living, apoptotic, and necrotic cells among scramble and siGFP U23674 cells were also similar. (G) Levels of cleaved
Caspase 3 (Cl-Casp 3) and cleaved PARP (Cl-PARP) were similar among control, scramble, and si-GFP U23674 cells. Etoposide-treated U23674 cells were included as
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Conversely, higher levels of P3F were associated with higher ex-
pression of Rnd2 (Fig 5F) (19), which regulates organization of the
actin cytoskeleton, and with higher expression of Itga5 (Fig 5G) (20,
21), Thbs3 (Fig 5H) (22, 23), Efemp1 (Fig 5I) (24), and Lama5 (Fig 5J) (25),
all involved in adhesion/cell–ECM interaction. Also, differences in
expression of myogenic regulatory factors between YFPhigh/P3Fhigh
and YFPlow/P3Flow cells were explored. Significantly higher levels of
myoblast determination protein 1 (MyoD1) and a trend towards
higher expression of paired-box transcription factor 7 (PAX7) and
myogenic factor 5 (Myf5) in YFPhigh/P3Fhigh cells were noted (Fig S9).
Next, chromatin accessibility sites in YFPhigh/P3Fhigh and YFPlow/
P3Flow cells were investigated by Assay for transposase-accessible
chromatin using sequencing (ATAC-Seq) (26). The Pax3 promoter
region showed higher ATAC-Seq signals in YFPhigh/P3Fhigh cells. As
P3F expression in mouse U23674 cells is directed by the endoge-
nous Pax3 promoter, this observation is consistent with higher
transcription of P3F in YFPhigh/P3Fhigh cells (Fig 5K). P3F fusion
protein DNA-binding motif also represented the most significantly
enriched motif in YFPhigh/P3Fhigh cells (Fig 5L). Overall, YFPhigh/
P3Fhigh cells contained ~30 times more chromatin accessible sites
than YFPlow/P3Flow cells (4,592 peaks in YFPhigh/P3Fhigh cells versus
142 peaks in YFPlow/P3Flow cells, Tables S5 and S6). Gene Set En-
richment Analysis demonstrated that genes involved in gene on-
tology (GO) categories for cell motility, locomotion, and adhesion
again were significantly enriched among those that had stronger
ATAC-Seq signals in YFPlow/P3Flow cells (Table S7).
Lower P3F expression changes the cytoarchitecture, adhesion,
and migration capacities of mouse RMS cells
Enrichment of genes involved in adhesion among those differen-
tially regulated between YFPlow/P3Flow and YFPhigh/P3Fhigh cells
pointed towards differences in cell adherence and migration ca-
pacity. As YFP/P3F expression in individual U23674 cells was un-
stable and fluctuated over time, we chose to investigate the
adhesion capacity of YFPlow/P3Flow and YFPhigh/P3Fhigh cells using
siRNA-mediated down-regulation of P3F expression. Indeed, siGFP
U23674 cells, in which P3F levels are suppressed, exhibited higher
cell surface areas than control, scramble U23674 cells (1.2 ± 0.8 mm2
versus 0.4 ± 0.2 mm2, P < 0.0001, Fig 6A). Also, when equal numbers
of siGFP and scramble U23674 cells were allowed to adhere to
the surface of a tissue culture plate for 2 h before toluidine blue
staining of adherent cells, siGFP U23674 cells displayed significantly
higher adhesion capacity than scramble U23674 cells (1.9 ± 0.09
versus 0.6 ± 0.1, P < 0.0001; Fig 6B).
Cell spreading and adhesion require the establishment of cir-
cumferential adhesion zones along the cell surface and may co-
incide with changes in cytoarchitecture. U23674 cells were stained
using paxillin and phalloidin antibodies to visualize focal adhesion
points (Fig 6C and D–F) and actin filaments (Fig 6D, G, and H), re-
spectively. Paxillin staining demonstrated a significantly higher
number of paxillin-rich focal adhesion points per cell in siGFP (Fig
6F, lower panel) compared with scramble (Fig 6F, middle panel)
U23674 cells (47.5 ± 25.3 versus 8.3 ± 5.8 adhesion points per cell, P <
0.01, Fig 6C). Phalloidin staining visualized thin, short actin fibers in
scramble U23674 cells (Fig 6H, middle panel), whereas robust actin
stress fibers were aligned throughout siGFP U23674 cells (Fig 6H,
lower panel). The observation that siGFP U23674 cells exhibited
highly organized actin stress fibers (Fig 6H, lower panel) and more
focal adhesion points (Fig 6F, lower panel) is consistent with the
more effective spreading and adhesion of cells expressing lower
P3F doses. As adhesion and spreading capacities of cells impact on
their ability to migrate, we also plated U23674 cells in serum-free
media on Boyden transwell migration filters to investigate transwell
migration. Significantly higher numbers of siGFP (Fig 6I, far right
panels) compared with scramble (Fig 6I, middle panels) U23674
cells migrated through pores (98 ± 31.6 versus 43 ± 11.8, P < 0.0001,
Fig 6I and J).
A second low-passage cell line established from Myf6Cre,Pax3:
Foxo1,p53 mouse sarcoma cells (U21459) was used to confirm that
lower P3F dose by siGFP silencing (Fig S10A) correlated with higher
cell surface areas (0.75 ± 0.61 mm2 versus 0.2 ± 0.09 mm2, P < 0.0001,
Fig S10B), more efficient adhesion to plastic surfaces (P < 0.0001; Fig
S10C), increased numbers of paxillin-rich focal adhesions per cell
(24 ± 6.7 versus 4.6 ± 3.6 focal adhesions per cell, P < 0.0001, Fig S10D
and E–G), increased stretching of the actin cytoskeleton (Fig
S10H–J), and higher migration activity (133 ± 15 versus 9 ± 5 mi-
grated cells per well, P < 0.0001; Fig S10K and L) compared with
scramble cells. Lower P3F dose in U21459 cells (Fig S11A) also
correlated with lower Itga8 (Fig S11B), Cdh4 (Fig S11C), and Rnd2 (Fig
S11D) as well as higher Itga5 (Fig S11E) and Thbs3 (Fig S11F)
expression.
However, lower P3F dose did not correlate with more efficient
adhesion to uncoated plastic surfaces and surfaces covered with
collagen I, collagen II, collagen IV, fibronectin, laminin, tenascin, or
vitronectin in the high-passage human RMS cell lines Rh5 (Fig S12A
and B), Rh30 (Fig S12C and D), and Rh41 (Fig S12E and F). As long-
term ex-vivo passage may have introduced artefacts, we also
attempted to silence P3F expression in human, low-passage primary
RMS cell cultures and evaluate differences in adhesion capacity. Un-
fortunately, these experiments were hampered by substantial toxicity
and poor cell survival. After siP3F silencing of fusion oncogene ex-
pression in CF1 cells (Fig S13A), we did not detect any differences in
adhesion to uncoated plastic surfaces (Fig S13B).
Reversal of adhesive phenotype of P3Flow cells by chemical
disruption of the actin cytoskeleton in mouse RMS cells
TR100 belongs to a class of anti-tropomyosin compounds, which
targets cytoskeletal tropomyosin-containing filaments in cancer
cells with high specificity (36) (Fig 7A–O). Increased stretching of the
actin cytoskeleton in siGFP U23674 cells (Fig 7O, upper panel) was
disrupted by TR100 treatment in siGFP U23674 cells (Fig 7O, lower
panel). Also, the increase in paxillin-rich adhesion points observed
positive controls. Differences in the percentage of living/apoptotic and necrotic cells were evaluated for statistical significance by ordinary one-way ANOVAs (ns P ≥ 0.05).
Differences in cell growth were evaluated by nonlinear regression (ns P ≥ 0.05, ****P < 0.001). Experiments were replicated three to five times. See Fig S6 for transient
silencing of P3F in human Rh30 and Rh5 RMS cells and its effects on proliferation and apoptosis.
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Figure 5. Transcriptional profiling identifies differences in the expression of genes involved in cell surface/matrix interaction in YFPhigh/P3Fhigh versus YFPlow/P3Flow
mouse U23674 RMS cells.
(A) The gene expression profiles of YFPhigh/P3Fhigh and YFPlow/P3Flow cells were distinct as evidenced by principal component analysis. (B) Pathway analysis of genes
differentially regulated in YFPhigh/P3Fhigh versus YFPlow/P3Flow cells revealed enrichment of transcripts involved in cell junction and extracellular matrix (based on the GO
cellular components database). (C) RT-QPCR confirmed silencing of P3F in si-GFP compared to control and scramble U23674 cells. (D, E, F, G, H, I, J) RT-QPCR also
confirmed differential expression of candidate genes in (D, E) cell-to-cell adhesion (Itga8 and Cdh4), (F) cytoskeletal organization (Rnd2), and (G, H, I, J) cell-to-extracellular
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in siGFP U23674 cells (Fig 7M, upper panel) was reduced in TR100-
treated U23674 cells (Fig 7M, lower panel). There were 16.4 ± 3.8
adhesions points per cell in TR100-treated U23674s compared with
35 ± 5.6 adhesion points per cell in DMSO-treated siGFP U23674s (P <
0.01, Fig 7P). In fact, the number of focal adhesion points per cell was
similar in TR100-treated siGFP and DMSO-treated scramble U23674
cells (e.g., 16.4 ± 3.8 versus 15 ± 1 adhesion points in TR100-treated
siGFP versus DMSO-treated scramble cells, P > 0.9, Fig 7P). Further-
more, more efficient adhesion of siGFP U23674 cells to the surface of
the culture dishes was reduced in TR100-treated siGFP U23674 cells (P
< 0.0001, Fig 7Q), so that the adhesion capacity of TR100-treated siGFP
U23674 cells was similar to that of scramble DMSO-treated U23674
cells (P = 0.03, Fig 7Q). Finally, the higher migration activity seen in
transwell migration assays of siGFP U23674 cells (Fig 7U, left panel)
was abrogated by exposure to TR100 (Fig 7S–U, right panel). We
observed 16 ± 4 migrated cells per well for TR100-treated U23674s
compared with 70 ± 16migrated cells per well for DMSO-treated siGFP
cells (P < 0.0001, Fig 7R). Migration of TR100-treated siGFP cells and
DMSO-treated scramble cells were similar (e.g., 16 ± 4 versus 11 ± 3
migrated cells per well for TR100-treated siGFP comparedwith DMSO-
treated scramble cells, P > 0.99, Fig 7R).
Similar results were obtained with TR100 treatment of U21459
mouse RMS cells (Fig S14A–R). Again, the organization of the actin
cytoskeleton (Fig S14R upper panel) and increased number of focal
adhesion points (Fig S14O upper panel, Fig S14S) observed in siGFP
U21459 cells was reversed by exposure to TR100 (Fig S14R and O
lower panels, Fig S14S). Also, more efficient adhesion to the surface
of tissue culture dishes (Fig S14T) and increased transwell migration
(Fig S14U–X) seen in siGFP U21459 was reduced by treatment with
TR100.
Discussion
The tumor cell pool in any given cancer is phenotypically and
functionally heterogeneous. This heterogeneity arises as a con-
sequence of hierarchical organization, clonal evolution, adaption to
microenvironmental, and systemic cues and/or reversible changes
in tumor cell properties (27). Cells within the RMS cell pool are
known to differ in their expression of cell surface antigens (28),
mutational spectrum (11), and degree of tissue-specific differen-
tiation (29). We confirm that low-passage mouse Myf6Cre+/−,Pax3:
Foxo1+/+,p53−/− RMS cell lines and low-passage human RMS cell
cultures contain cells expressing markedly heterogeneous P3F
levels (17). Within the Myf6Cre+/−,Pax3:Foxo1+/+,p53−/− RMS cell
pool, a large portion of YFPhigh/P3Fhigh cells are in the G2/M phases
of the cell cycle, and higher P3F expression correlates with higher
proliferation rates. By contrast, YFPlow/P3Flow U23674 cells are
mostly in the G0/G1 phases of the cell cycle (17) and reorganize their
cytoarchitecture to produce a cellular phenotype prone to adhe-
sion and migration. These differences translate into higher clonal
activity and increased tumor-propagating capacity of P3Flow U23674
cells. Chemical disruption of the actin cytoskeleton, for example, by
exposure to the anti-tropomyosin compound TR100 (30), reduced
the ability of YFPlow/P3Flow mouse RMS cells to adhere and migrate.
TR100 and other actin-depolymerizing agentsmay be of therapeutic
value in RMS.
At the single cell level, P3F levels fluctuate over time (15). Kikuchi
et al reported that P3F expression increased in pre-mitotic cells. P3F
was highly expressed in the G2 cell cycle phase, which correlated
with increased Pax3 promoter activity in G2 and was shown to
mediate cell cycle adaptation and survival of cells exposed to
genomic stress (15). Our observations suggest that variable P3F
expression within the RMS cell pool involves transition between
phenotypes prone to adhesion and phenotypes predisposed to
proliferation. Such adaptive plasticity may provide tumors with a
critical advantage during progression through different malignant
stages and may allow tumor cells to adapt to environmental
challenges. P3Flow cells may drive metastatic spread at an early
stage, which might explain why patients with PAX-translocated RMS
frequently harbor micrometastatic disease at first presentation and
develop metastases very early (31, 2). Exposure to chemotherapy
drugs was shown to change the proportion of P3Fhigh and P3Flow
cells, which may contribute to the development of drug resistances.
Interestingly, the melanoma cell pool was recently shown to
contain transcriptionally distinct populations of cells, which
transition between proliferative and invasive phenotypes to drive
melanoma progression (32, 33, 34, 35, 36). Slow-cycling melanoma
cells with an invasive phenotype expressed high levels of the re-
ceptor tyrosine kinase AXL (37), which was one of the most strongly
up-regulated genes in YFPlow/P3Flow compared with YFPhigh/P3Fhigh
mouse RMS cells (logFC 2.6, Table S3). Also, Franzetti et al proposed
that Ewing sarcomas, a class of bone sarcomas typically expressing
the EWS:FLI1 fusion oncoprotein, displayed phenotypic plasticity
because of dynamic fluctuations in EWS:FLI1 expression at the
single cell level (38). EWS:FLI1low cells were less cohesive and
expressed higher levels of actin-binding proteins involved in the
assembly of the cytoskeleton compared with EWS:FLI1high cells (38).
The transition from proliferative to invasive phenotypes was trig-
gered by environmental cues such as extracellular matrix stiffness
(33), presence of certain extracellular ligands (e.g., TGFβ) (33), and
nutrient/oxygen availability (25). We note that cell densities, glu-
tamine availability, chemical exposures, and certain extracellular
matrix components also influenced the proportion of YFPhigh/
P3Fhigh and YFPlow/P3Flow cells within themouseMyf6Cre+/−,Pax3:
Foxo1+/+,p53−/− RMS cell pool. Yet, the mechanisms driving
matrix interaction (Itga5, Thbs3, Efemp1, and Lama5) in si-GFP compared with control and scramble U23674 cells. (K) Assay for transposase-accessible chromatin using
sequencing (ATAC-Seq) demonstrated higher ATAC-Seq signals in the PAX3 promoter region in YFPhigh/P3Fhigh cells. (L) P3F fusion protein DNA-binding motif represented
the most significantly enriched motif in YFPhigh/P3Fhigh cells. PCR data were evaluated for statistical significance by ordinary one-way ANOVAs (ns P ≥ 0.05, *P < 0.05, **P <
0.01, ***P < 0.001, ****P < 0.0001). See Figs S5 and S6 for the differential expression of transcripts involved in focal adhesion and in the regulation of the actin
cytoskeleton, respectively, in YFPhigh/P3Fhigh versus YFPlow/P3Flow cells. See Table S3 for a list of genes differentially regulated genes in YFPhigh/P3Fhigh versus YFPlow/P3Flow
cells (logFC < −1 or >1, false discovery rate [FDR] < 0.01); see Table S4 for pathways enriched in genes differentially regulated (logFC < −1 or >1, FDR < 0.01) in YFPhigh/P3Fhigh
versus YFPlow/P3Flow cells (FDR < 0.05); see Tables S5 and S6 for genes with stronger ATAC-Seq signals in YFPlow/P3Flow and YFPhigh/P3Fhigh U23674 cells; see Table S7 for
pathways enriched among genes with stronger ATAC-Seq signals in YFPlow/P3Flow cells.
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Figure 6. Lower P3F dose in mouse U23674 RMS cells changed cytoarchitecture, adhesion and migration.
(A) The cell surface area of si-GFP U23674 cells was higher than that of control and scramble U23674 cells 2 h after plating. (B) Also, the number of adherent si-GFP cells
was higher than that of control and scramble cells, as evidenced by Toluidine Blue staining 2 h after plating. (C, D, E, F) Si-GFP cells (F, bottom panel) containedmore focal
adhesion points per cell compared to control and scramble cells (F, upper and middle panels), as visualized by Paxillin immunocytochemical staining. (G, H) Phalloidin
staining revealed re-organization of the actin cytoskeleton with formation of robust stress fibers in si-GFP cells (H, bottom panel) compared with control and scramble
cells (H, upper and middle panels). (I, J) Si-GFP cells (I, far right panels) exhibited higher migration capacity than control and scramble cells (I, far left and middle panels).
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fluctuating P3F expression inmouse RMS remain unclear. It is important
to note that the endogenous Pax3 promoter, which drives P3F ex-
pression in Myf6Cre+/−,Pax3:Foxo1+/+,p53−/− mouse RMS cells (14),
displayed higher ATAQ-Seq signals in YFPhigh/P3Fhigh U23674 cells. We
speculate that changes in P3F expression may be a consequence of
core regulatory circuits that establish and maintain cellular prop-
erties through their extended regulatory networks (39).
P3Flow RMS cells are mostly in the G0/G1 phases of the cell cycle,
prone to adhesion and with higher tumor-propagating potential
than P3Fhigh cells. It is conceivable that they represent a stem-like
cellular state. This is interesting, as increasing evidence supports
that extracellular matrix proteins provide a physical and bio-
chemical niche to promote stem cell survival by establishing
anchorage/homing sites that serve as a reservoir for external
factors, allow for formation of focal adhesions and mediate acti-
vation of mechanotransduction pathways (40). The ability to bind to
extracellular matrix components was previously linked to clono-
genic activity and tumor-forming capacity in sarcoma cells.
Buchstaller et al demonstrated that laminin-negative malignant
peripheral nerve sheet tumor (MPNST) cells displayed lower tumor-
forming capacity thanin laminin-positive MPNST cells. Lower tumor-
forming capacity of laminin-negative MPNST cells was augmented by
coinjecting cells with laminin/Matrigel into mouse recipient animals
(41).
Cell-to-cell heterogeneity in P3F expression was present within
the mouseMyf6Cre,Pax3:Foxo1,p53 RMS cell pool, but also in human
primary RMS cell cultures and RMS cell lines. However, one im-
portant limitation of our studies is that we were unable to re-
produce a correlation between lower P3F expression and higher
capacity to adhere to a variety of different surface matrices in
human RMS cell lines Rh30, Rh41, or Rh5, which could be due to
fundamental differences in mouse and human tumors or, more
likely, due to artefacts introduced by long-term passage of the
human cell lines in vitro. Our subsequent attempts to silence P3F
expression in low-passage human primary RMS cell cultures
were hampered by substantial toxicities and poor survival of
siP3F-transfected cells. P3F silencing in CF1 primary human RMS
cells was not associated with changes in cell adhesion to plastic
surfaces. Of note, melanoma studies also indicated that ectopic
expression of the melanoma transcriptional master regulator
microphthalmia-associated transcription factor (MITF) did not
necessarily induce phenotype switching, possibly because epigenetic
modifications were necessary for MITF to drive the transition be-
tween phenotypes (32). Further single-cell analyses will be needed to
clarify differences in gene expression signatures linked to distinct
phenotypes within the RMS cell pool.
Taken together, our studies highlight variable P3F expression
at the cellular level in human primary RMS cell cultures and
Myf6Cre+/−,Pax3:Foxo1+/+,p53−/− mouse RMS tumors, and we dem-
onstrate the functional consequences of this heterogeneity with
respect to tumorigenic and invasive potential. Importantly, higher
proportions of cells in the G0/G1 phase of the cell cycle among YFPlow/
P3Fhigh cells may contribute to their higher tumor-propagating and
clonogenic capacity. Because of its central role in RMS malignancy,
the P3F fusion oncogene has generally been considered an ideal
target to selectively attack tumor cells. Yet, our data clearly indicate
that eliminating P3Fhigh cells only by targeting the fusion oncogene
may not cure the disease. This is supported by published observa-
tions in genetically engineered mouse RMS tumors, which regressed
after withdrawal of inducible P3F followed by rapid recurrence with-
out re-activation of P3F (42). It will be important to understand the
mechanisms that direct fluctuations in P3F expression at the cellular
level, to design treatment regimens, that might be able to overcome
plasticity, for example, by using metronomic therapies that avoid




NOD/CB17-Prkdcscid/J (NOD.SCID) mice were bred and maintained
at the Center for Experimental Models and Transgenic Service
(CEMT) Freiburg. All animal experiments were approved by the
Regierungspräsidium Freiburg (G-16/136).
Cell lines
Mouse U23674 and U21459 RMS cell lines were established in mouse
sarcomas, which arose spontaneously in Myf6Cre,Pax3:Foxo1,p53
mice (Table S1). In thesemice, expression ofMyf6-Cre converted the
two normally functioning Pax3 alleles into conditional P3F knock-in
alleles by fusing exons 1–7 of Pax3 to a 9.3-kb 39 genomic region of
Foxo1. P3F was linked to an eYFP fluorescent marker gene, which
was expressed as a second cistron downstream from an IRES. The
mice also carried conditional Tp53 knockouts on both alleles. For
the experiments reported here, U23674 cells were used at passage
13–24, and U21459 at passage 7–24. U23674 and U21459 cells were
grown in DMEM (41965-039; Gibco), supplemented with 10% FBS
(F7524; Sigma-Aldrich), and 1% Penicillin/Streptomycin (PS, 15140-
122; Gibco).
SJRHB013759_X1 primary RMS cell cultures were established from
a recurrent inguinal P3F fusion-positive RMS tumor diagnosed in a
19-yr-old male, IC-pPDX 35 primary RMS cell cultures from a re-
current P3F fusion-positive RMS tumor diagnosed in a 13-yr-old
male, RMSZH003 from a recurrent pelvic P3F fusion-positive RMS
tumor diagnosed in a 3-yr-old female and CF1 from a 1.8-yr-old boy
with disseminated disease (43). For the experiments reported here,
SJRHB013759_X1 cells were used at passage 5–9, IC-pPDX 35 cells at
passage 3–9, RMSZH003 cells at passage 4–7 and CF1 at passage 7–15
Data were evaluated for statistical significance by ordinary one-way ANOVA statistical test (ns P ≥ 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001). Experiments were
replicated three times. See Fig S9 for the effects of P3F silencing on the cytoarchitecture, adhesion, and migration of mouse U21459 cells. See Fig S10 for the effects of P3F
silencing on the expression of candidate genes involved in cell-to-cell adhesion, cytoskeletal organization, and cell-to-extracellular matrix interaction in mouse U21459
cells. See Fig S11 for the effects of P3F silencing on the adhesion capacities of human Rh5, Rh30, and Rh41 cells. See Fig S12 for the effects of P3F silencing on the
adhesion capacities of CF1 human patient-derived RMS cell cultures.
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(Table S1). SJRHB013759_X1, IC-pPDX 35, and RMSZH003 were cul-
tured in Neurobasal Medium (10888022; Gibco) supplemented with
1% penicillin/streptomycin (15140-122; Gibco), 1× Glutamax (35050;
Gibco), 2× B27 (17504044; Life Technologies), 20 ng/ml bFGF (AF-100-
18B; Peprotech), and 20 ng/ml EGF (AF-100-15; Peprotech). CF1 were
grown in RPMI supplemented with 10% FBS and 1% PS.
Mouse C2C12 cells and human RD cells (used as YFPneg control
cells), mouse Kras(G12v); P16p19nullmouse RMS cells (used as YFPpos
Figure 7. Chemical disruption of the
actin cytoskeleton in U23674 mouse
RMS cells reversed the effects of lower
P3F dose on cell adhesion and
migration.
(A, B, C, D, E, F, G, H, I, J, K, L, M, N, O)
Visualization of the actin cytoskeleton
and focal adhesion points per cell by
phalloidin and paxillin staining of
U23674 cells treated with the anti-
tropomyosin compound TR100 or
carrier only (DMSO). (O) TR100
disrupted increased stretching of
the actin cytoskeleton in siGFP cells.
(M) TR100 also reversed the higher
number of focal adhesion points per cell
in siGFP cells. (P) Quantification of
focal adhesion points per cell
confirmed that TR100 reduced the
higher number of adhesion points
observed in DMSO-treated siGFP cells
to numbers than those observed in
control and scramble cells treated
with DMSO. (Q, R, S, T, U) Exposure to
TR100 also abrogated (Q) more efficient
adhesion and (R, S, T, U) higher
migration capacity of DMSO-treated
siGFP cells to levels similar to those
observed in control and scramble
cells treated with DMSO. Data were
evaluated for statistical significance by
ordinary one-way ANOVAs (ns P ≥
0.05, *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001). Experiments were
replicated three times. See Fig S13 for
the effects of TR100 treatment on
organization of the actin cytoskeleton,
adhesion and migration in mouse
U21459 cells.
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control cells [44]); and human HEK293T cells were grown in DMEM
supplemented with 10% FBS and 1% PS. Rh5, Rh30 and Rh41 human
RMS cells (Table S1) were grown in DMEM supplemented with 20%
FBS and 1% PS.
Short tandem repeat analyses of human (Table S8) and mouse
(Table S9) cell lines used in this study was performed by Eurofins.
FACS
Cells were suspended in HBSS with 2% FBS. Antibody staining was
performed for 20 min on ice. Before FACS sorting, cells were labeled
with 7AAD (559925; BD Biosciences) to exclude dead cells. Cells were
sorted twice using a MoFlo Astrios flow cytometer. Purity checks
were performed to confirm that the sorted YFPpos and YFPneg cell
subsets had a purity of >98% using a YFP expression threshold
determined by the background fluorescence of YFPneg C2C12 cells.
Cell cycle analysis
U23674 cells were stained with Hoechst 33342 (H1339; Invitrogen)
at a final concentration of 5 μg/ml for 45 min at 37°. Cells were
then centrifuged at 300g for 5 min and resuspended in HBSS sup-
plementedwith 2% FBS. FACS analysis was performed on LSRFortessa
from Becton Dickinson.
Clonal assays
Twenty U23674 cells per well were sorted into 96-well plates and
allowed to expand into clones. Formation of clones was evaluated
after 6–11 d using a microscope (Axiovert 40C Microscope; Carl
Zeiss). Clones were harvested 11 d after plating and subjected to
RNA isolation or flow cytometry analysis.
Sarcoma transplantation
Sarcoma cells were sorted, reconstituted in HBSS with 2% FBS, and
injected at defined numbers into the gastrocnemius muscles of
1–3-mo-old, anesthesized NOD.SCID mice as previously described
(44). Recipient tissue was preinjured 24 h before cell injection with
25 μl of a 0.03 mg/ml solution of cardiotoxin (from Naja naja
mosambica; Sigma-Aldrich). Mice were followed up for up to 4 mo
after transplantation. The extremity muscles of mice that did not
develop palpable tumors were dissected 4mo after transplantation
to exclude tumors.
Tumor-bearing mice were euthanized, and tumors were har-
vested. Tumor tissue was digested in DMEM supplemented with
0.2% collagenase type II (17101-015; Gibco) and 0.05% Dispase
(17105-041; Gibco) for 90 min at 37° in a shaking water bath and
mechanically dissociated as described before (22). Red blood cells
were removed using ammonium-chloride-potassium (ACK) Lysing
Buffer (A1049201; Thermo Fisher Scientific) for 3 min on ice.
Transcriptional profiling and pathway analysis
Total RNAwas isolated using TRIzol Reagent (15596018; Ambion) and
quantified using a 2.0 Qubit fluorometer (Invitrogen). RNA integrity
was confirmed using an Agilent 2100 Bioanalyzer. Kit, Clariom S
Assay, andmouse array (902931; Affymetrix) was performed according
to the manufacturer’s instructions. CEL files were processed with the
Oligo R package (45) and intensity were RMA normalized. A linear-
based model (46) was used to identify differentially regulated genes
in YFPhigh/P3Fhigh versus YFPlow/P3Flow. Regulated genes with a fold-
change (logFC) < −1 or >1 and a FDR < 0.01 were selected for gene set
analysis using Fisher’s exact test. Databases were downloaded from
MSigDB (47) Consensus pathDB (48). Raw data are accessible on gene
expression omnibus (GEO) using the following GSE ID: GSE153894.
Transposase-accessible chromatin using sequencing (ATAC-Seq)
ATAC-Seq was performed on mouse U23674 YFPhigh/P3Fhigh and
YFPlow/P3Flow cells as previously described (26). Briefly, 23k cells
were collected and centrifuged at 500g for 5 min at 4°C. The su-
pernatant was discarded without disturbing the cell pellets, which
were resuspended in 50 μl of cell lysis buffer (Tris–HCl, pH 7.4, 10mM
NaCl, 3 mM MgCl2, and 0.1% NP40) and centrifuged at 500g for 5 min
at 4°C. The supernatant was removed carefully and resuspended in
freshly prepared Tn5 reaction buffer (12.5 μl 1X TD buffer [Illumina],
1 μl Tn5 transposase, and 11.5 μl nuclease-free water). The trans-
position reaction was incubated at 37°C for 30 min and then pu-
rified using the Zymo ChIP clean up kit. Transposed DNA was
subjected to five cycles of indexed PCR amplification using New
England Biolabs Next Ultra II Q5 Master Mix and custom-indexed
primers. Quantitative RT–PCR was performed to determine the
optimal number of PCR cycles for linear amplification without
saturating ATAC-Seq libraries. ATAC-Seq libraries were then quan-
tified using Qubit (Invitrogen), normalized, pooled, and sequenced
on an Illumina HiSeq 4000 sequencer (paired-end 125 bp, on average
100 M reads per library). FASTQ files were processed by trimming
Illumina adapters and Tn5 sequences with trimmomatic before
alignment to the mouse genome (build mm10) using bowtie2. Du-
plicate and mitochondrial reads were removed. The HOMER pipeline
was used to determine transcription factor motifs, which were
enriched in specific cell types (49). Gene Set Enrichment Analysis was
performed as previously described (47, 50). Raw data are accessible
on GEO using the following GSE ID: GSE154452.
Si-RNA silencing and retroviral transduction
SiRNA-silencing was performed using Lipofectamine RNAiMax
Transfection Reagent (13778030; Invitrogen) according to the manu-
facturer’s instructions. SiRNAs were obtained from Dharmacon (ON-
TARGET plus nontargeting control pool for the scramble and si-GFP).
pMSCV-Flag-IRES-GFP retrovirus was produced in HEK293T cells,
cotransfected with pMSCV-Flag-IRES-GFP (29.3 μg), pCMV-Gag-Pol
(9.75 μg), and pMD2.VSV.G (4.9 μg). Retrovirus-containing super-
natant was concentrated by ultracentrifugation at 19,500 rpm (rMAX
161, rMIN 75.3, rAV 118.2mm) using a Sorvall WX Ultra Series 80
centrifuge (Thermo Fisher Scientific) for 3 h at 4°C.
Annexin V staining
Apoptosis was evaluated by Annexin V-APC staining (550474; BD
Bioscences) according to the manufacturer’s protocol using a FACS
canto flow cytometer. 7AAD was used for viability staining. U23674
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and Rh30 cells treated with etoposide at a concentration of 50 μM
were used as positive controls.
Western blotting
Cell pellets were lysed using cell lysis buffer (9803S; New England
Biolabs) supplemented with protease/phosphatase inhibitor cock-
tail (5872S; Cell Signaling Technology). Proteins were resolved on
SDS-polyacrylammide gels and blotted onto Immuno-Blot poly-
vinylidene difluoride (PVDF) membranes (1620177; Bio-Rad), which
were blocked with PBST 3% non-fat dry milk, incubated with
primary antibodies overnight at 4°C, washed, and hybridized for
1 h at room temperature using goat anti-mouse/rabbit immuno-
globulin G (IgG) (H + L)–HRP Conjugate (1706516/15; Bio-Rad)
depending on the origins of the primary antibody. Detection was
performed using the ECL Select Western Blotting Detecting
Reagent (RPN2235; Amersham). The following antibodies were
used: anti-β actin (1:50,000, AC15; Sigma-Aldrich), anti-Pax3:Foxo1
(1:500, C29H4; Cell Signaling Technology), anti-PARP (1:1,000, 9542;
Cell Signaling Technology), and anti-Cleaved Caspase 3 (1:500,
9664; Cell Signaling Technology).
Real-time PCR
Total RNA was isolated using TRIzol Reagent (15596018; Ambion)
according to the manufacturer’s instructions and quantified using a
NanoDrop Spectrophotometer (Thermo Fisher Scientific). RNA was
reverse-transcribed using Superscript III First Strand (18080051; Invi-
trogen). Real-time PCR was performed using SybrGreen (4309155;
Thermo Fisher Scientific). The relative expression of each gene was
defined from the threshold cycle (Ct), and relative expression levels
were calculated by using the 2-DDCtmethod.MouseGapdh or Actinwas
used as housekeeping genes. Primer sequences are listed in Table S10.
Single-cell reverse transcriptase droplet digital PCR (RT-ddPCR)
One RMS cell per well was sorted in 96-well plates containing
4.5 μl Single-Cell Lysis Buffer and 0.5 μl Single-Cell DNase I (Single-
Cell Lysis Kit, 4458235; Ambion) using a Moflo Astrios. The reaction
was stopped by adding 0.5 μl of single-cell stop solution. cDNA
synthesis was performed after adding 2.5 μl of RT reaction mix
(iScript Advanced cDNA Synthesis kit, 1725038; Bio-Rad) for a total
volume of 10 μl. Droplet digital PCR amplification of Pax3:Foxo1
(FAM) and Gapdh (HEX) was performed in a final volume of 25 μl by
adding the ddPCR Supermix for Probes No UDP (Bio-Rad), the FAM
and HEX probes to the cDNA mix. Droplets were generated using
the QX100 Droplet Generator (Bio-Rad) with 70 μl Droplet Generation
Oil (Bio-Rad) and 40 μl of the resulting water-in-oil droplet emulsion
was then thermocycled at 95°C for 10min, followed by 40 cycles of 95°C
for 30 s and61.3°C for 1min. Final enzymedeactivation took place at 98°
for 10 min. Individual droplets were analyzed using the Q100 Droplet
Reader and Quantasoft Software. The following probe sequences were
used: 59-/56-FAM/CATTGGCAA/ZEN/TGGCCTCTCACCTCAGAA/3IABkFQ/-39
(P3F FAM probe), 59-/5HEX/ACCACAGTC/ZEN/CATGCCATCACTGCCACC/
3IABkFQ/-39 (GAPDH HEX probe).
Immunocytochemistry
Cells were fixed using 4% PFA, permeabilized with 0.2% Triton X-100,
blocked with Vector M.O.M. Immunodetection Kit (BMK-2202) containing
10% goat serum, and incubated with Alexa Fluor 488–conjugated anti-
phalloidin (1:1,000, A12379; Thermo Fisher Scientific) at room temperature
for 1 h, Alexa Fluor 594-conjugated anti-Phalloidin (1:100, ab176757;
Abcam) at room temperature for 1 h or anti-Paxillin (1:100, 610051; BD
Biosciences) at 4°C overnight. Alexa Fluor 594 goat anti-mouse IgG
(1:200) was used for secondary antibody staining at room temperature
for 1 h. Antibodies were diluted in Vector M.O.M. Immunodetection Kit
(BMK-2202) containing 10% goat serum. Nuclei were stained with Dapi.
Images were obtained using a Zeiss LSM 710 confocal microscope.
Adhesion assays
Cells were seeded at 100,000 cells per well using non-coated 24-
well plates and allowed to adhere to the plate for 2 h at 37° before
removal of the supernatant and non-adherent cells. To quantify
adhesion, cells were fixed with 4% PFA for 30 min, washed with PBS,
stained with Toluidine Blue for 1 h, air dried overnight, and dis-
solved in 2% SDS solution. Optical density was measured at 620 nm.
To evaluate cell surface areas, adherent cells were imaged using a
HBO 100 AXIO microscope (Carl Zeiss), and cell surface areas were
measured for 15 representative fields using ImageJ.
For the human Rh5, Rh30, and Rh41 sarcoma cell lines, adhesion
assays were carried out using the ECM Cell Adhesion Array Kit
(ECM540; Millipore) according to the manufacturer’s instructions.
Briefly, cells were seeded at 20,000 cells per well, allowed to adhere
for 2 h at 37° and stained according to the manufacturer’s in-
structions. The absorbance was then measured at 560 nm. For each
well, the ratio between the absorbances obtained for cells grown on
coated and non-coated surfaces was calculated.
Migration assay
Cells were seeded at 300,000 cells per well in serum-free medium
using cell culture inserts (353093; Falcon) in six-well plates. Cells
were allowed to migrate for 8 h at 37°. Migrated cells were then
stained with crystal violet for 30 min. Excess crystal violet was
removed, and the inserts were air dried overnight. Cells were im-
aged using a HBO 100 AXIO microscope (Carl Zeiss).
Drug exposures
U23674 cells were pretreated with 10 μM TR100 (SML1065; Sigma-
Aldrich) and U21459 cells with 15 μM TR100 for 12 h and then seeded
for paxillin/phalloidin immunocytochemistry staining, adhesion,
andmigration assays as described above. Control cells were treated
with vehicle (DMSO) only.
To evaluate thedrug effects on theproportionof YFPhigh/P3Fhigh and
YFPlow/P3Flow U23674 RMS cells, U23674 cells were seeded at 30,000
cells/well in 96-well plates and then treated with 2.5 nM dactinomycin
(Recordati) for 48 h, 5 nM vincristine (Tewa Ratiopharm) for 48 h, or
10 μM TR100 for 12 h. Control cells were treated with vehicle only. The
percentage of YFPhigh/P3Fhigh U23674 RMS cells wasmeasured by FACS.
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Environment effects on the proportion of YFPhigh/P3Fhigh U23674
RMS cells
To evaluate nutrient effects, cells were seeded at 50,000 cells/well
in six-well plates (flat bottom) in medium containing 0.5 mM glu-
tamine and 25 nM glucose. After 24 h, themediumwas replaced with
medium containing increasing concentrations of glutamine (0.05,
0.5, and 4 mM) and 25 nM glucose. Alternatively, the medium was
replaced with a medium containing increasing concentrations of
glucose (2.8, 25 nM) and 0.5 mM glutamine. To evaluate cell density
effects, cells were seeded at 10,000 cells/well in flat bottom and
triangle bottom 96-well plates in DMEM. Alternatively, cells were
plated in flat bottom 96-well plates in DMEM at increasing cell
densities as indicated. Finally, to evaluate matrix effects, surfaces
were coated with laminin 50 μg/ml (L2020; Sigma-Aldrich), Matrigel
(354234; Corning), and fibronectin 5 μg/ml (FC010; Millipore). The
percentage of YFPhigh/P3Fhigh U23674 RMS cells was evaluated by
FACS 72 h after changing the medium or 48 h after seeding.
Statistics
Differences in % YFP expression, candidate gene expression by RT-
QPCR, proportion of Annexin V-/7AAD-living cells, proportion of
Annexin V+/7AAD-apoptotic cells, proportion of Annexin V+/7AAD+
necrotic cells, cell surface areas, cell adhesion, number of focal
adhesions/cell as evidenced by paxillin staining, and cell migration
were tested for significance using one-way ANOVAs with Bonfer-
roni’s multiple comparisons. Environmental differences in the
percentage YFPhigh/P3Fhigh and YFPlow/P3Flow cells and changes in
the adhesion capacity of human RMS cells were tested for sig-
nificance using two-tailed t test for unpaired data. Differences in
cell growth were evaluated by nonlinear regression analysis. Dif-
ferences in clonal activity were tested for significance using a chi
square test. Differences in tumor-propagating capacity were
evaluated statistically using log-rank (Mantel–Cox) tests. Limiting
dilution analyses were performed based on Bonnefoix et al (51)
using the limdil function of the StatMod package (author GK Smyth,
http://bioinf.wehi.edu.au/software/limdil/). For single-cell digital
droplet PCR data, P3F expression was normalized based on GAPDH
expression, and cell-to-cell variability was illustrated using the
interquartile range of the normalized expression median.
Data Availability
The datasets produced in this study are available in the following
databases: Raw RNA-Seq data are accessible on GEO using the
following GSE ID: GSE153894. Raw ATAQ-Seq data are accessible on
GEO using the following GSE ID: GSE154452.
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